Aldeyra Therapeutics Appoints Stephen Tulipano As CFO - Quick Facts

(RTTNews) - Aldeyra Therapeutics, Inc. (ALDX), Thursday named Stephen Tulipano as its Chief Financial Officer, effective June 23, 2014.

Tulipano has 12 years of experience in the pharmaceutical industry. Most recently, he held positions at Three Tulips Inc., an accounting and management advisory services firm, where he provided full-time accounting services and financial management counsel. Before that, he was the Chief Financial Officer of Javelin Pharmaceuticals, where he helped lead the company through its acquisition by Hospira in 2010. Earlier, he had served in the role of Director of Corporate Accounting at Biogen Idec, one of the oldest bio-pharmaceutical companies in the U.S.

Commenting on the appointment, Todd Brady, President and Chief executive of Aldeyra, said: "...Given his proven track record of managing a company's finances during clinical trials, Steve will be a tremendous asset as we advance the clinical development of our lead product candidate, NS2, for the treatment of Sjogren-Larsson Syndrome and acute anterior uveitis."